甲状腺癌肿瘤干细胞的来源和存活途径

doi:10.16352/j.issn.1001-6325.2022.02.017

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (2): 321-324.doi: 10.16352/j.issn.1001-6325.2022.02.017

甲状腺癌肿瘤干细胞的来源和存活途径

谢丽君^*, 朱高红, 赵继华, 张海波, 王娇

昆明医科大学第一附属医院核医学科, 云南昆明 653002

收稿日期:2021-06-15 修回日期:2021-11-02 出版日期:2022-02-05 发布日期:2022-01-24
通讯作者: ^* 421894079@qq.com
基金资助:
云南省科技厅-昆医联合专项(20201AY070001-039)

Origin and survival pathways of cancer stem cells in thyroid cancers

XIE Li-jun^*, ZHU Gao-hong, ZHAO Ji-hua, ZHANG Hai-bo, WANG Jiao

Department of Nuclear Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming 653002, China

Received:2021-06-15 Revised:2021-11-02 Online:2022-02-05 Published:2022-01-24
Contact: ^* 421894079@qq.com

摘要/Abstract

摘要： 目前越来越多关于肿瘤干细胞的研究得到了关注。已有研究证明不管预后良好的分化型甲状腺癌还是预后不良的未分化或失分化甲状腺癌均存在肿瘤干细胞。甲状腺癌肿瘤干细胞在肿瘤的发生、进展和转移中起主要作用,甚至可能是甲状腺癌的复发和耐药的根源,因此甲状腺肿瘤干细胞的研究对甲状腺癌的诊疗具有重要意义。在本文中,笔者对最新的甲状腺癌肿瘤干细胞的来源和存活途径的研究进展进行了综述。

关键词: 甲状腺癌, 肿瘤干细胞, 来源, 存活途径

Abstract: More and more attentions were being paid to the study of tumor stem cells. It has been demonstrated that tumor stem cells were present in both differentiated thyroid cancer with a good prognosis as papillary or follicular cancer and undifferentiated ones with poor prognosis. Thyroid cancer stem cells (TCSCs) play a major role in tumor genesis, progression and metastasis, and may even be the root of recurrence and drug resistance in thyroid cancers. Therefore, the study of TCSCs is great importance to thyroid cancer treatment. In this paper, the authors reviewed the latest researches progress on the origin and survival pathways of TCSCs.

Key words: thyroid cancers, cancer stem cells, origin, survival pathway

中图分类号:

R736.1

谢丽君, 朱高红, 赵继华, 张海波, 王娇. 甲状腺癌肿瘤干细胞的来源和存活途径[J]. 基础医学与临床, 2022, 42(2): 321-324.

XIE Li-jun, ZHU Gao-hong, ZHAO Ji-hua, ZHANG Hai-bo, WANG Jiao. Origin and survival pathways of cancer stem cells in thyroid cancers[J]. Basic & Clinical Medicine, 2022, 42(2): 321-324.

参考文献

[1]Coelho M, Raposo L, Goodfellow BJ, et al. The potential of metabolomics in the diagnosis of thyroid cancer[J]. Int J Mol Sci, 2020,21:5272.doi:10.3390/ijms21155272.
[2]Asa SL. The current histologic classification of thyroid cancer[J]. Endocrinol Metab Clin North Am, 2019,48: 1-22.
[3]高伟波, 陈书长, 赵春华. 肿瘤干细胞与肿瘤耐药[J]. 基础医学与临床, 2006, 26:662-667.
[4]Han SA, Jang JH, Won KY, et al. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid car-cinoma[J]. Pathol Res Pract, 2017,213:956-963.
[5]Hardin H, Helein H, Meyer K, et al. Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of incRNAs[J]. Lab Invest, 2018, 98: 1133-1142.
[6]Cho JM, Lee HJ, Chung JH, et al. Papillary thyroid cancer tumor spheres cultured by passaging without sorting exhibit cancer stemness[J]. Anticancer Res, 2020, 40:3801-3809.
[7]Haghpanah V, Fallah P, Naderi M, et al. Cancer stem-like cell behavior in anaplastic thyroid cancer: a challenging dilemma[J]. Life Sci, 2016, 146:34-39.
[8]Todaro M, Iovino F, Eterno V, et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells.[J]. Cancer Res, 2010, 70:8874-8885.
[9]Yuji N, Mika S, Norisato M. Cancer stem cells in the thyroid[J]. Front Endocrinol(Lausanne), 2016, 7:20.doi:10.3389/fendo.2016.00020.
[10]Shimamura M, Nagayama Y, Matsuse M, et al. Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines[J]. Endocr J, 2014, 61:481-490.
[11]Shiraiwa K, Matsuse M, Nakazawa Y,et al. JAK/STAT3 and NF-κB signaling pathways regulate cancer stem-cell properties in anaplastic thyroid cancer cells.[J]. Thyroid, 2019,29:674-682.
[12]Rao AS, Kremenevskaja N, von Wasielewski R, et al. Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer[J]. J Clin Endocrinol Metab, 2006, 91:159-168.
[13]许力凡, 张记, 田志强,等. 肿瘤抗药性的表观遗传学调控机制[J]. 基础医学与临床, 2013, 33:1638-1641.
[14]Zhu G, Xie L, Miller D. Expression of microRNAs in thyroid carcinoma[J].Methods Mol Biol, 2017, 1717: 261-280.
[15]Ravi N, Yang M, Mylona N, et al. Global RNA expression and DNA methylation patterns in primary anaplastic thyroid cancer[J]. Cancers, 2020, 12:680.doi:10.3390/cancers12030680.
[16]Kotian S, Zhang L, Boufraqech M,et al. Dual Inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases[J]. Clin Cancer Res,2017,23:5044-5054.
[17]Lin CL, Tsai ML, Lin CY, et al. HDAC1 and HDAC2 double knockout triggers cell apoptosis in advanced thyroid cancer[J]. Int J Mol Sci, 2019, 20. doi: 10.3390/ijms20020454.
[18]Xie Z, X Li, He Y, et al. Immune cell confrontation in the papillary thyroid carcinoma microenvironment[J]. Front Endocrinol(Lausanne), 2020,11:570604. doi: 10.3389/fendo.2020.570604.
[19]Varricchi G, Loffredo S, Marone G, et al. The immune landscape of thyroid cancer in the context of immune checkpoint inhibition[J]. Int J Mol Sci, 2019, 20:3934. doi:10.3390/ijms20163934.
[20]Kim MJ, Sun HJ, Song YS, et al. CXCL16 positively correlated with M2-macrophage infiltration, enhanced angiogenesis, and poor prognosis in thyroid cancer[J]. Sci Rep,2019, 16;9:13288. doi: 10.1038/s41598-019-49613-z.
[21]Croce L, Coperchini F, Magri F, et al. The multifaceted anti-cancer effects of BRAF-inhibitors[J]. Oncotarget, 2019, 10:6623-6640.
[22]Mario R, Francesca C, Francesco L, et al. Role of chemokines in thyroid cancer microenvironment:is CXCL8 the main player?[J]. Front Endocrinol(Lausanne), 2018, 9:314. doi: 10.3389/fendo.2018.00314.
[23]Bauerle KT, Schweppe RE, Lund G, et al. Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8.[J]. J Clin Endocrinol Metab, 2014,99:E1436-1444.
[24]Zheng R, Chen G, Li X, et al. Effect of IL-6 on proliferation of human thyroid anaplastic cancer stem cells[J]. Int J Clin Exp Pathol, 2019, 12:3992-4001.

甲状腺癌肿瘤干细胞的来源和存活途径

Origin and survival pathways of cancer stem cells in thyroid cancers

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张燕萍, 姚刘旭, 丁倩男, 黄则勇, 李玉红, 黄素琴. 结直肠癌PDX模型成瘤率的影响因素及临床意义[J]. 基础医学与临床, 2023, 43(4): 596-602.
[2]	田艳, 马姣姣, 席雪华, 张波. 超声检查评估分化型甲状腺癌颈部转移淋巴结的研究进展[J]. 基础医学与临床, 2023, 43(3): 505-508.
[3]	陈施静, 傅菁岚, 邓媛媛, 张颖, 刘慧霞. 维生素D-24-羟化酶与甲状腺癌的相关性研究进展[J]. 基础医学与临床, 2023, 43(3): 490-494.
[4]	王世尊, 张丹, 葛明, 冯海凉, 刘玉琴. 可移植人髓母细胞瘤PUMC-MBT1瘤株的建立与鉴定[J]. 基础医学与临床, 2022, 42(9): 1339-1343.
[5]	周美岑, 兰玲, 邓微. RNA结合蛋白在甲状腺癌发病机制中作用的研究进展[J]. 基础医学与临床, 2022, 42(8): 1306-1309.
[6]	李昱阳, 李钊璇, 罗云萍, 陈翀. 小鼠乳腺癌干细胞免疫相关分子表达和免疫浸润的分析[J]. 基础医学与临床, 2022, 42(6): 876-882.
[7]	傅菁岚, 邓媛媛, 张颖, 章鑫煦, 陈施静, 刘慧霞. 甲状腺癌与糖尿病的相关性研究进展[J]. 基础医学与临床, 2022, 42(4): 667-670.
[8]	尹婕, 潘凌亚, 温仪萍, 黄虹, 曾靖, 李晓莹, 韩甜甜, 金滢, 李艳. 人上皮性卵巢癌细胞系侧群细胞的肿瘤干细胞样细胞生物学特性及膜蛋白差异表达的鉴定[J]. 基础医学与临床, 2022, 42(2): 221-227.
[9]	刘亚琪, 郑承红. miR-205通过靶向调控Wnt-5a抑制乳头状甲状腺癌的细胞增殖[J]. 基础医学与临床, 2021, 41(3): 358-363.
[10]	傅松波, 马承旭, 井高静, 赵楠, 汤旭磊, 牟军勤, 常寅龙. 苦参碱对人乳头状甲状腺癌细胞系TPC-1增殖和迁移的影响[J]. 基础医学与临床, 2021, 41(12): 1730-1735.
[11]	赵钊, 刘帆, 纪志刚, 张震宇, 黄钟明, 石冰冰. 泌尿生殖系统孤立性纤维瘤的临床特征和治疗策略[J]. 基础医学与临床, 2020, 40(7): 975-979.
[12]	曹邓晗, 陈奎生. miR-135b-3p调控XAF1表达影响甲状腺癌细胞的迁移、侵袭和放射增敏性[J]. 基础医学与临床, 2020, 40(6): 790-796.
[13]	曹邓晗, 陈奎生. miR-197-3p调控DMBT1抑制甲状腺癌细胞系增殖、迁移和侵袭[J]. 基础医学与临床, 2020, 40(5): 644-650.
[14]	董保龙, 韩彩文, 史明, 郑文学, 杨晓军. 波形蛋白在肝细胞癌中的研究进展[J]. 基础医学与临床, 2020, 40(2): 238-242.
[15]	张晨郭建赫慧文王胜男陈惠琳段昭君罗云萍. M2型巨噬细胞来源外泌体对乳腺癌细胞系4T1干性特征的影响[J]. 基础医学与临床, 2019, 39(6): 798-804.